Company profile

BeOne Medicines Ltd.

Pipeline26 assets

ZanubrutinibBTK / Inhibitor / Hematologic Malignancies / Immunology & Inflammation
Treatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Waldenström Macroglobulinemia and Treatment-Naïve Waldenström MacroglobulinemiaApproved
SonrotoclaxBCL2 / Inhibitor / Hematologic Malignancies
Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaApproved
TislelizumabPD-1 / Monoclonal Antibody / Lung Cancers / Gastrointestinal Cancers / Other Cancers
First-Line Extensive-Stage Small Cell Lung CancerApprovedFirst-Line Non-Squamous Non-Small Cell Lung CancerApprovedFirst-Line Squamous Non-Small Cell Lung CancerApproved
BGB-16673BTK Chimeric Degradation Activation Compound [CDAC] / Hematologic Malignancies / Immunology & Inflammation
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Mantle Cell LymphomaPhase 2
BlinatumomabCD19 x CD3 / BiTE® [Bispecific T-Cell Engager] / Hematologic Malignancies
Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (subcutaneous formulation)Phase 2
TarlatamabDLL3 x CD3 / BiTE® [Bispecific T-cell Engager] / Lung Cancers
First-Line Extensive-Stage Small Cell Lung CancerPhase 3First-Line Extensive-Stage Small Cell Lung CancerPhase 3Second-Line Small Cell Lung CancerPhase 3
ZanidatamabHER2 Bispecific / Antibody / Gastrointestinal Cancers
First-Line HER2 Positive Gastroesophageal AdenocarcinomaPhase 3Second-Line HER2 Positive Biliary Tract CancerApprovedFirst-Line HER2 positive Biliary Tract CancerPhase 3
BG-68501CDK2 / Inhibitor / Breast/Gynecologic Cancers
Breast Cancer and Solid TumorsPhase 1
BGB-21447BCL2 / Inhibitor / Breast/Gynecologic Cancers
Hormone Receptor Positive Breast CancerPhase 1
BGB-43395CDK4 / Inhibitor / Breast/Gynecologic Cancers
Breast Cancer and Solid TumorsPhase 1
BGB-B455Claudin 6 x CD3 Bispecific / Antibody / Breast/Gynecologic Cancers
Gynecologic and Solid TumorsPhase 1
BG-C9074B7-H4 Antibody Drug Conjugate / Breast/Gynecologic Cancers
Breast Cancer and Solid TumorsPhase 1
BG-75202KAT6A/B / Inhibitor / Breast/Gynecologic Cancers
Breast CancerPhase 1
BG-75098CDK2 Chimeric Degradation Activation Compound [CDAC] / Breast/Gynecologic Cancers
Breast CancerPhase 1
BGB-B2033GPC3 x 4-1BB Bispecific / Antibody / Gastrointestinal Cancers
Solid TumorsPhase 1
BG-C137FGFR2b Antibody Drug Conjugate / Gastrointestinal Cancers
Gastrointestinal CancersPhase 1
BGB-53038Pan-KRAS / Inhibitor / Gastrointestinal Cancers
Lung Cancers and GI CancersPhase 1
BG-C477CEA Antibody Drug Conjugate / Gastrointestinal Cancers
Lung Cancers and GI CancersPhase 1
BG-C0902EGFR x MET x MET Antibody Drug Conjugate / Lung Cancers
Lung Cancers and GI CancersPhase 1
BG-T187EGFR x MET x MET Trispecific / Antibody / Lung Cancers
Lung Cancers and GI CancersPhase 1
BGB-58067MTA Cooperative PRMT5 / Inhibitor / Lung Cancers
Lung Cancers and GI CancersPhase 1
BG-89894MAT2A / Inhibitor / Lung Cancers
Lung Cancers and Solid TumorsPhase 1
BG-60366EGFR Chimeric Degradation Activation Compound [CDAC] / Lung Cancers
Lung CancersPhase 1
BGB-26808HPK1 / Inhibitor / Gastrointestinal Cancers
Solid Tumors/Pan- TumorPhase 1
XaluritamigSTEAP1 x CD3 Bispecific T-cell Engager (XmAb®) / Other Cancers
Metastatic Castration-Resistant Prostate CancerPhase 1
BGB-45035IRAK4 Chimeric Degradation Activation Compound [CDAC] / Immunology & Inflammation
Rheumatoid ArthritisPhase 2Skin DiseasesPhase 1

Latest news0 items

All news

No recent headlines yet.

New company coverage will appear here as soon as it is picked up.